- Trials with a EudraCT protocol (66)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
66 result(s) found for: Functional behavior assessment.
Displaying page 1 of 4.
EudraCT Number: 2018-004519-31 | Sponsor Protocol Number: ENTERL08784 | Start Date*: 2019-01-31 | |||||||||||
Sponsor Name:Sanofi | |||||||||||||
Full Title: Randomized, placebo-controlled, clinical trial to evaluate the efficacy of probiotic Bacillus clausii in the treatment of pediatric patients with irritable bowel syndrome | |||||||||||||
Medical condition: Irritable bowel syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000567-26 | Sponsor Protocol Number: 2010-021883-14 | Start Date*: 2013-01-31 | |||||||||||
Sponsor Name:Radboud University Medical Centre Nijmegen | |||||||||||||
Full Title: A randomized double-blind, placebo-controlled study of risperidone in the treatment of DSM-IV-TR conduct disorder in children and adolescents. | |||||||||||||
Medical condition: Conduct Disorder DSM-IV-TR; 312.8x¸ APA, 2000 | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004804-31 | Sponsor Protocol Number: SHP-ELA-401 | Start Date*: 2016-04-12 |
Sponsor Name:Shire Human Genetic Therapies, Inc. (Shire), a wholly owned subsidiary of Takeda Pharmaceutical Company Limited | ||
Full Title: A Long-Term, Open-Label, Multicenter, Phase IV Study to Assess Longitudinal Changes on Height and Weight in Patients with MPS II Who Are Receiving Elaprase and Started Treatment With Elaprase at <6... | ||
Medical condition: Hunter syndrome (Mucopolysaccharidosis II, [MPS II]) | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-005346-37 | Sponsor Protocol Number: F1D-MC-HGMR | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Eli Lilly and Company Limited | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Maintenance of Effect Study of Olanzapine in the Treatment of Disruptive Behavioral Symptoms in Children and Adolescents with Pervasive Developmental ... | |||||||||||||
Medical condition: children and adolescents with disruptive behavioral symptoms associated with Pervasive Developmental Disorders (PDD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001989-38 | Sponsor Protocol Number: IMCRELA | Start Date*: 2021-07-08 | |||||||||||
Sponsor Name:Facultad de medicina y ciencias de la salud de la Universidad Católica de Valencia | |||||||||||||
Full Title: IMPACT OF THE COMBINED TREATMENT OF THE LIPOSOMATED POLYPHENOLS CÚRCULA AND RESVERATROL® WITH DUTASTERIDE, IN THE CLINICAL IMPROVEMENT OF PATIENTS WITH ALS TREATED WITH RILUZOLE | |||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003280-38 | Sponsor Protocol Number: PSY-NIL-0006 | Start Date*: 2016-05-04 | |||||||||||
Sponsor Name:Medical University of Vienna | |||||||||||||
Full Title: Positron Emission Tomography assessment of Ketamine Binding of the Serotonin Transporter and its Relevance for Rapid Antidepressant Response | |||||||||||||
Medical condition: 20 patients with severe unipolar depression (structured clinical interview for DSM-IV and the 17-item Hamilton Depression Rating Scale), also 20 age and sex matched healthy controls. plus 12 HC f... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001056-17 | Sponsor Protocol Number: 3606 | Start Date*: 2020-08-14 | ||||||||||||||||
Sponsor Name:Kings's College London [...] | ||||||||||||||||||
Full Title: A randomised feasibility trial investigating Sativex® for the treatment of the Agitation & Aggression (A/A) in Alzheimer’s Dementia. | ||||||||||||||||||
Medical condition: Clinically significant agitation in Alzheimer's Diseases | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000867-21 | Sponsor Protocol Number: NGAM-13 | Start Date*: 2021-08-16 |
Sponsor Name:Octapharma Pharmazeutika Produktionsges.m.b.H. | ||
Full Title: A Superiority Study To Compare The Effect of Panzyga Versus Placebo in Patients with Pediatric Acute-onset Neuropsychiatric Syndrome | ||
Medical condition: Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS). PANS is a research diagnosis given to patients who have an abrupt, dramatic onset of neuropsychiatric symptoms including obsessions/compulsio... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA SE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002485-39 | Sponsor Protocol Number: TAK-935-18-001(OV935)Amendment1 | Start Date*: 2019-06-14 |
Sponsor Name:Ovid Therapeutics, Inc. | ||
Full Title: A PHASE 2, PROSPECTIVE, INTERVENTIONAL, OPEN-LABEL, MULTI-SITE, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF TAK-935 (OV935) AS ADJUNCTIVE THERAPY IN PATIENTS WITH RARE EPILEP... | ||
Medical condition: developmental and epileptic encephalopathies | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) PL (Trial now transitioned) PT (Trial now transitioned) Outside EU/EEA | ||
Trial results: (No results available) |
EudraCT Number: 2022-002780-30 | Sponsor Protocol Number: 9515 | Start Date*: 2022-12-01 | |||||||||||
Sponsor Name:Aarhus University Hospital, The Research Clinic for Functional Disorders and Psychosomatics | |||||||||||||
Full Title: Efficacy of patient education and duloxetine, alone and in combination, for patients with multiorgan bodily distress syndrome: a partial-factorial randomized controlled trial (the EDULOX-trial) | |||||||||||||
Medical condition: Multiorgan Functional somatic disorders (FSD) / bodily disstress syndrome (BDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011411-21 | Sponsor Protocol Number: BVF-324-302 | Start Date*: 2009-07-17 | |||||||||||
Sponsor Name:Biovail Laboratories International SRL, c/o Biovail Technologies Ltd | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Two Doses of Tramadol Hydrochloride Orally Disintegrating Tablets in Male Subjects with Pre... | |||||||||||||
Medical condition: Premature Ejaculation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: HU (Prematurely Ended) BG (Prematurely Ended) CZ (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011410-18 | Sponsor Protocol Number: BVF-324-301 | Start Date*: 2009-07-29 | |||||||||||
Sponsor Name:Biovail Laboratories International SRL, c/o Biovail Technologies Ltd | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Two Doses of Tramadol Hydrochloride Orally Disintegrating Tablets in Male Subjects with Pre... | |||||||||||||
Medical condition: Premature Ejaculation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: BE (Completed) DE (Prematurely Ended) FR (Completed) SE (Prematurely Ended) ES (Completed) GB (Prematurely Ended) NL (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003826-18 | Sponsor Protocol Number: 111-206 | Start Date*: 2018-09-12 | |||||||||||
Sponsor Name:BioMarin Pharmaceutical Inc. | |||||||||||||
Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children with Achondroplasia, Age 0 to < 60 Months | |||||||||||||
Medical condition: Achondroplasia | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004837-34 | Sponsor Protocol Number: CAEB1102-300A | Start Date*: 2019-06-18 | |||||||||||
Sponsor Name:Aeglea Biotherapeutics, Inc. | |||||||||||||
Full Title: PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and ... | |||||||||||||
Medical condition: Arginase 1 Deficiency Hyperargininemia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002251-11 | Sponsor Protocol Number: TPN-101-C9-201 | Start Date*: 2021-12-06 | ||||||||||||||||
Sponsor Name:Transposon Therapeutics, Inc | ||||||||||||||||||
Full Title: A Phase 2a Study of TPN-101 in Patients with C9ORF72 ALS/FTD (Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia) | ||||||||||||||||||
Medical condition: Amyotrophic lateral sclerosis or frontotemporal dementia due to a genetic mutation called C9orf72 hexanucleotide repeat expansion | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) FR (Completed) ES (Ongoing) BE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001128-30 | Sponsor Protocol Number: BIIT001 | Start Date*: 2008-05-07 |
Sponsor Name:SE Dept. of Psychiatry and Psychotherapy | ||
Full Title: EFFICACY OF SERTINDOLE AS COMPARED TO OLANZAPINE OR RISPERIDONE ON PREATTENTIONAL AND ATTENTION-DEPENDENT FUNCTIONS IN PATIENTS WITH CHRONIC SCHIZOPHRENIA. A COGNITIVE AND FMRI STUDY. | ||
Medical condition: schizophrenia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004143-13 | Sponsor Protocol Number: SHP-609-302 | Start Date*: 2015-03-19 | ||||||||||||||||
Sponsor Name:Shire Human Genetic Therapies, Inc. | ||||||||||||||||||
Full Title: An Open Label Extension of Study HGT-HIT-094 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Idursulfase Administered in Conjunction with Elaprase® in Patients with Hunter Syndrome... | ||||||||||||||||||
Medical condition: Hunter syndrome and cognitive impairment | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) FR (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-001634-10 | Sponsor Protocol Number: M15-566 | Start Date*: 2017-08-23 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimer's Disease | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) ES (Completed) BE (Completed) DK (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001263-23 | Sponsor Protocol Number: BP27832 | Start Date*: 2014-03-19 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF RO5186582 IN ADULTS AND ADOLESCENTS WITH DOWN SYNDROME (CLEMATIS) | |||||||||||||
Medical condition: Down Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002044-28 | Sponsor Protocol Number: HGT-MLD-070 | Start Date*: 2012-06-14 | |||||||||||
Sponsor Name:Shire Human Genetics Therapies Inc | |||||||||||||
Full Title: A Phase I/II, Multicenter, Open-label, Dose Escalation Study of HGT-1110 Administered Intrathecally in Children with Metachromatic Leukodystrophy | |||||||||||||
Medical condition: Treatment of Metachromatic Leukodystrophy | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
